Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
Emergent BioSolutions entered a strategic manufacturing agreement with Substipharm Biologics valued at approximately $34.5 million to produce the Japanese Encephalitis vaccine IMOJEV at its Canton facility. The deal grants Emergent exclusive distribution rights to the U.S. government upon potential FDA approval, leveraging the facility's recent "No Action Indicated" status following a February inspection.
Key figures
- Deal Value Usd
- 34500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.